~~Imprelis~~^{®
^3.
The company has received claims and lawsuits alleging that the use of Imprelis^® herbicide caused damage to certain trees. Sales of Imprelis^® were suspended in August 2011 and the product was last applied during the 2011 spring application season. The lawsuits seeking class action status were consolidated in multidistrict litigation in federal court in Philadelphia, Pennsylvania. In February 2014, the court entered the final order dismissing these lawsuits as a result of the class action settlement.

As part of the settlement, DuPont paid about $7 in plaintiffs' attorney fees and expenses. DuPont also provided a warranty, which expired on May 31, 2015, against new damage, if any, caused by the use of Imprelis^® on class members' properties. In the third quarter 2014, the company settled the majority of claims from class members that opted out of the class action settlement. About 30 opt-out actions are pending at June 30, 2015, a decrease of 10 from December 31, 2014.

DuPont recorded income of $35 for insurance recoveries, within other operating charges in the interim Consolidated Income Statements, for the six months ended June 30, 2015. At June 30, 2015, DuPont had an accrual balance of $216 related to these claims and insurance receivables of $15.

Insurance recoveries are recognized when collection of payment is considered probable. The remaining coverage under the insurance program is $300 for costs and expenses. DuPont has submitted requests for payment to its insurance carriers for costs associated with this matter. The timing and outcome remain uncertain. Guarantee for Chemours' raw material purchase obligations under agreement with third party supplier.

Litigation
The company is subject to various legal proceedings arising out of the normal course of its business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Although considerable uncertainty exists, management does not anticipate that the ultimate disposition of these matters will have a material adverse effect on the company's results of operations, consolidated financial position or liquidity. However, the ultimate liabilities could be material to results of operations in the period recognized.

PFOA
DuPont used PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt), as a processing aid to manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. At June 30, 2015,March 31, 2016, DuPont has an accrual balance of $14$14 related to the PFOA matters discussed below. Pursuant to the Separation Agreement discussed in Note 3, the company is indemnified by Chemours for the PFOA matters discussed below. As a result, the company has recorded an indemnification asset of $14 corresponding to the accrual balance as of March 31, 2016.

The accrual includes charges related to DuPont's obligations under agreements with the U.S. Environmental Protection Agency and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Provisional Health Advisory.

Drinking Water Actions
In August 2001, a class action, captioned Leach v DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23$23 and made a payment of $70,$70, which class counsel designated to fund a community health project. The company funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease.

The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia; kidney cancer; testicular cancer; thyroid disease; ulcerative colitis; and diagnosed high cholesterol.

14
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share)

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. The company is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative costs associated with the program, including class counsel fees. In January 2012, the company established and put $1 ininto an escrow account to fund medical monitoring as required by the settlement agreement.

16
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share)

Under the settlement agreement, the balance in the escrow amount must be at least $0.5; as a result, transfers of additional funds may be required periodically. The court appointed Director of Medical Monitoring has established the program to implement the medical panel's recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account.account; at March 31, 2016, less than $1 has been disbursed.

In addition, under the settlement agreement, the company must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA), and private well users.

Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At June 30, 2015March 31, 2016 and MarchDecember 31, 2015, there were approximately 3,500 lawsuits pending in various federal and state courts in Ohio and West Virginia. The number ofThese lawsuits pending at June 30, 2015, reflects the filing of about 50 additional cases and plaintiffs' voluntary dismissal of about 40 cases during the second quarter 2015. In accordance with a stipulation reached in the third quarter 2014 and other court procedures, these lawsuits have been or will be served andare consolidated in multi-district litigation in Ohio federal court (MDL). Based on information currently available to the company the majorityAbout 75 percent of the lawsuits allege personal injury claims associated only with high cholesterol andand/or thyroid disease from exposure to PFOA in drinking water. At JuneAs a result of plaintiffs' corrected pleadings and further discovery, the company has revised downward to 30 2015, 37the estimated number of the pending lawsuits allegealleging wrongful death. While attorneys for the plaintiffs have indicated that additional lawsuits may be filed, the rate of such filings has substantially decreased.

In 2014, six plaintiffs from the MDL were selected for individual trial. The jury awarded $1.6 in compensatory damages in the first individual trial, captioned Bartlett v DuPont, which was tried to a verdict in October 2015. The plaintiff alleged that exposure to PFOA in drinking water had caused kidney cancer. DuPont, through Chemours, is appealing the decision. The second matter selected for trial, Wolf v DuPont, involved allegations that exposure to PFOA in drinking water caused ulcerative colitis, a confidential settlement for an inconsequential amount was reached and substantially completed in Wolf v DuPont. Three cases are scheduled for trial in 2016 starting in May, August and November, respectively; the plaintiffs in each of these cases allege exposure to beginPFOA in September 2015, anddrinking water caused cancer.

In January 2016, the secondcourt determined that 40 cases in November 2015. which plaintiffs assert cancer claims, would be scheduled for trial in 2017, beginning in April of that year. Less than 10 percent of the 3,500 pending lawsuits involve claims that exposure to PFOA in drinking water caused cancer.

DuPont, through Chemours, denies the allegations in these lawsuits and is defending itself vigorously.

Additional Actions
AnIn the first quarter 2016, a confidential settlement was reached in the Ohio action brought by the LHWA is ongoing. In addition to general claims of PFOA contamination of drinking water, the action claimsclaiming, “imminent and substantial endangerment to health and or the environment” under the Resource Conservation and Recovery Act (RCRA). In the second quarter 2014, DuPont filed a motion for summary judgment and LHWA moved for partial summary judgment. In the first quarter in addition to general claims of 2015, the court granted in part and denied in part both parties’ motions. As a result, the litigation process is continuing with respect to certainPFOA contamination of drinking water. The cost of the plaintiffs’ claims and trial has been set for October 2015.settlement was paid by Chemours.

PFOA Summary
While it is probable that the company will incur costsliabilities related to funding the medical monitoring program, such costsliabilities cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing. DuPont believes that it is reasonably possible that it could incur lossesadditional liabilities related to the other PFOA matters discussed above; however, a range of such losses,liabilities, if any, cannot be reasonably estimated at this time, due to the uniqueness of the individual MDL plaintiff's claims and the company's defenses to those claims both as to potential liability and damages on an individual claims basis, among other factors. As noted above, the company is indemnified by Chemours for these PFOA matters.

Environmental
The company is also subject to contingencies pursuant to environmental laws and regulations that in the future may require the company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the company or other parties. The company accrues for environmental remediation activities consistent with the policy as described in the company's 20142015 Annual Report in Note 1, “Summary of Significant Accounting Policies.” Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), Resource Conservation and Recovery Act (RCRA)RCRA and similar state and global laws. These laws require the company to undertake certain investigative, remediation and restoration activities at sites where the company conducts or once conducted operations or at sites where company-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified by the company for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

1517
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share)

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of potentially responsible parties. At June 30, 2015,March 31, 2016, the Condensed Consolidated Balance Sheet included a liability of $477,$492, relating to these matters and, in management's opinion, is appropriate based on existing facts and circumstances. The average time frame over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15-2015-20 years. Considerable uncertainty exists with respect to these costs and, under adverse changes in circumstances, the potential liability may range up to $1,100$1,025 above the amount accrued as of June 30, 2015.March 31, 2016. Pursuant to the Separation Agreement discussed in Note 3, the company is indemnified by Chemours for certain environmental matters, included in the liability of $492, that have an estimated liability of $282 as of March 31, 2016 and a potential exposure that ranges up to approximately $618 above the amount accrued. As such, the company has recorded an indemnification asset of $282 corresponding to the company’s accrual balance related to these matters at March 31, 2016.

16
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share)

Note 11.12. Stockholders’ Equity
Share Repurchase Program
In January 2014, the company's Board of Directors authorized a $5,000 share buyback plan that replaced the 2011 plan. During the three and six months ended June 30, 2015 the company purchased and retired 1.0 million and 4.6 million shares, respectively, in the open market, which offset the dilution from employee compensation plans in the first and second quarter of 2015. As of June 30, 2015, the company has purchased 34.7 million shares at a total cost of $2,353 under the plan. There is no required completion date for the remaining stock purchases.

Share Buyback Plan
In the first quarter 2015, DuPont announced its intention to buy back shares of about $4,000 using the distribution proceeds received from Chemours. In connection with the completion of the spin-off of Chemours, the Board of Directors authorized the use of the distribution proceeds to buy back shares of the company's common stock as follows: $2,000 to be purchased and retired by December 31, 2015, which was completed during 2015, with the remainder to be purchased and retired by December 31, 2016. There were no share repurchases under this plan in the first quarter 2016. As of March 31, 2016, in aggregate, the company has paid $2,000 and received and retired 35 million shares.

Other Comprehensive Income (Loss)2014 Share Buyback Plan
A summaryIn January 2014, the company's Board of Directors authorized a $5,000 share buyback plan that replaced the changes2011 plan. During the three months ended March 31, 2015, the company purchased and retired 3.6 million shares in other comprehensive income (loss)the open market for a total cost of $282, which offset the dilution from employee compensation plans in the first quarter of 2015. There were no share repurchases under this plan in the first quarter 2016. As of March 31, 2016, in aggregate, the company has purchased 34.7 million shares at a total cost of $2,353 under the plan. There is no required completion date for the three and six months ended June 30, 2015 and 2014 is provided as follows:
Three Months Ended Three Months Ended Affected Line Item in Consolidated Income Statements
June 30, 2015 June 30, 2014
Pre-Tax Tax After-Tax Pre-Tax Tax After-Tax
Cumulative translation adjustment⁽³⁾ $ 197
$ —
$ 197
$ (59 ) $ —
$ (59 )
Net revaluation and clearance of cash flow hedges to earnings:
Additions and revaluations of derivatives designated as cash flow hedges 8
(3 ) 5
(12 ) 4
(8 ) See (1) below
Clearance of hedge results to earnings:
Foreign currency contracts (2 ) 1
(1 ) 1
(1 ) —
Net sales
Commodity contracts 7
(3 ) 4
12
(4 ) 8
Cost of goods sold
Net revaluation and clearance of cash flow hedges to earnings 13
(5 ) 8
1
(1 ) —

Pension benefit plans:
Net (loss) gain (2 ) 1
(1 ) (103 ) 33
(70 ) See (1) below
Effect of foreign exchange rates (62 ) 18
(44 ) —
—
—
See (1) below
Reclassifications to net income:
Amortization of prior service (benefit) cost (1 ) —
(1 ) —
—
—
See (2) below
Amortization of loss 210
(75 ) 135
150
(52 ) 98
See (2) below
Curtailment loss —
—
—
4
(1 ) 3
See (2) below
Settlement loss 4
(1 ) 3
2
—
2
See (2) below
Pension benefit plans, net 149
(57 ) 92
53
(20 ) 33

Other benefit plans:
Reclassifications to net income:
Amortization of prior service benefit (52 ) 18
(34 ) (53 ) 19
(34 ) See (2) below
Amortization of loss 19
(6 ) 13
14
(5 ) 9
See (2) below
Other benefit plans, net (33 ) 12
(21 ) (39 ) 14
(25 )
Other comprehensive income (loss) $ 326
$ (50 ) $ 276
$ (44 ) $ (7 ) $ (51 ) remaining stock purchases.

1718
Table of Contents
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
(Dollars in millions, except per share)

Other Comprehensive Income (Loss)
A summary of the changes in other comprehensive loss for the three months ended March 31, 2016 and 2015 is provided as follows:
Six Months Ended Six Months Ended Affected Line Item in Consolidated Income Statements Three Months Ended Affected Line Item in Consolidated Income Statements
June 30, 2015 June 30, 2014 March 31, 2016 March 31, 2015
Pre-Tax Tax After-Tax Pre-Tax Tax After-Tax Pre-Tax Tax After-Tax Pre-Tax Tax After-Tax
Cumulative translation adjustment⁽³⁾⁽¹⁾ $ (992 ) $ —
$ (992 ) $ (131 ) $ —
$ (131 ) $ 170
$ —
$ 170
$ (1,189 ) $ —
$ (1,189 )
Net revaluation and clearance of cash flow hedges to earnings:
Additions and revaluations of derivatives designated as cash flow hedges (14 ) 3
(11 ) 26
(10 ) 16
See (1) below 16
(6 ) 10
(22 ) 6
(16 ) See (2) below
Clearance of hedge results to earnings:
Foreign currency contracts (10 ) 4
(6 ) 2
(1 ) 1
Net sales —
—
—
(8 ) 3
(5 ) Net sales
Commodity contracts 22
(9 ) 13
29
(11 ) 18
Cost of goods sold 11
(4 ) 7
15
(6 ) 9
Cost of goods sold
Net revaluation and clearance of cash flow hedges to earnings (2 ) (2 ) (4 ) 57
(22 ) 35
27
(10 ) 17
(15 ) 3
(12 )
Pension benefit plans:
Net (loss) gain (6 ) 2
(4 ) (102 ) 33
(69 ) See (1) below
Net loss (1,191 ) 428
(763 ) (4 ) 1
(3 ) See (2) below
Effect of foreign exchange rates 38
(9 ) 29
—
—
—
See (1) below 1
—
1
100
(27 ) 73
See (2) below
Reclassifications to net income:
Amortization of prior service (benefit) cost (3 ) 1
(2 ) 1
—
1
See (2) below
Amortization of prior service benefit (2 ) 1
(1 ) (2 ) 1
(1 ) See (3) below
Amortization of loss 419
(149 ) 270
299
(103 ) 196
See (2) below 172
(60 ) 112
209
(74 ) 135
See (3) below
Curtailment loss —
—
—
4
(1 ) 3
See (2) below 49
(17 ) 32
—
—
—
See (3) below
Settlement loss 9
(3 ) 6
2
—
2
See (2) below 1
(1 ) —
5
(2 ) 3
See (3) below
Pension benefit plans, net 457
(158 ) 299
204
(71 ) 133
(970 ) 351
(619 ) 308
(101 ) 207

Other benefit plans:
Net loss (124 ) 45
(79 ) —
—
—
See (2) below
Reclassifications to net income:
Amortization of prior service benefit (104 ) 37
(67 ) (106 ) 38
(68 ) See (2) below (39 ) 13
(26 ) (52 ) 19
(33 ) See (3) below
Amortization of loss 38
(13 ) 25
28
(9 ) 19
See (2) below 17
(7 ) 10
19
(7 ) 12
See (3) below
Curtailment gain (30 ) 10
(20 ) —
—
—
See (3) below
Other benefit plans, net (66 ) 24
(42 ) (78 ) 29
(49 ) (176 ) 61
(115 ) (33 ) 12
(21 )
Other comprehensive (loss) income $ (603 ) $ (136 ) $ (739 ) $ 52
$ (64 ) $ (12 )
Net unrealized loss on securities:
Unrealized loss on securities arising during the period (9 ) —
(9 ) —
—
—
See (4) below
Reclassification of gain realized in net income 1
—
1
—
—
—
Other income, net
Net unrealized loss on securities (8 ) —
(8 ) —
—
—

Other comprehensive loss $ (957 ) $ 402
$ (555 ) $ (929 ) $ (86 ) $ (1,015 )}

Segment Reviews

Summarized below are comments on individual segment net sales and ~~PTOI~~operating earnings for the three ~~and six~~ month period ended ~~June 30, 2015~~March 31, 2016 compared with the same period in ~~2014~~2015. Segment ~~PTOI~~operating earnings is defined as income (loss) from continuing operations before income taxes excluding significant pre-tax benefits (charges), non-operating pension and other postretirement employee benefit costs, exchange gains (losses), corporate expenses and interest. Non-operating pension and other postretirement employee benefit costs includes all of the components of net periodic benefit costs from continuing operations with the exception of the service cost component. Reclassifications of prior year data have been made to conform to current year classifications. See Note 15 to the interim Consolidated Financial Statements for details related to significant pre-tax benefits (charges) excluded from segment operating earnings. All references to prices are based on local price unless otherwise specified.

A reconciliation of segment ~~sales~~operating earnings to ~~consolidated net sales and segment PTOI to~~ income from continuing operations before income taxes for the three ~~and six~~ month periods ended ~~June 30, 2015~~March 31, 2016 and ~~2014~~2015 is included in Note 1415 to the interim Consolidated Financial Statements. ~~See Note 3 to the interim Consolidated Financial Statements for information related to the 2014 restructuring plan and the Chemours restructuring program.~~

~~Segment PTOI includes certain items which management believes are significant to understanding~~DuPont Sustainable Solutions, previously within the company's Safety & Protection segment ~~results discussed below. See Note 14 to~~(now Protection Solutions) was comprised of two business units: clean technologies and consulting solutions. Effective January 1, 2016, the ~~interim Consolidated Financial Statements and Note 21 to the Consolidated Financial Statements~~clean technologies business unit became part of the ~~company’s 2014 annual report for details related~~Industrial Biosciences segment with the focus on working with customers to ~~these items. These items are excluded from~~improve the ~~2015 segment outlooks below~~performance, productivity and sustainability of their products and processes. The company is exploring a range of options to maximize the growth of the consulting solutions business unit which ~~discuss management’s current expectations for full-year 2015 segment sales and PTOI compared to full-year 2014.~~effective January 1, 2016, is reported within Other.

The following table summarizes ~~second~~first quarter ~~and year-to-date 2015~~2016 segment net sales and related variances versus prior year:

Three Months Ended
June 30, 2015 Percentage Change Due to:

Segment
Sales
($ Billions)
Percent
Change vs.
2014
Local Price and Product Mix Currency Volume
Portfolio
and Other
Agriculture $ 3.2
(11 ) 1
(5 ) (6 ) (1 )
Electronics & Communications 0.5
(13 ) (4 ) (2 ) (7 ) —
Industrial Biosciences 0.3
(9 ) (3 ) (8 ) 2
—
Nutrition & Health 0.8
(11 ) (1 ) (9 ) —
(1 )
Performance Chemicals 1.5
(11 ) (6 ) (4 ) —
(1 )
Performance Materials 1.4
(14 ) (4 ) (7 ) 3
(6 )
Safety & Protection 0.9
(10 ) —
(5 ) —
(5 )


	Six Months Ended												Three Months Ended
	June 30, 2015				Percentage Change Due to:								March 31, 2016				Percentage Change Due to:
	Segment Sales ($ Billions)		Percent Change vs. 2014		Local Price and Product Mix		Currency		Volume		Portfolio and Other		Segment Net Sales ($ Billions)		Percent Change vs. 2015		Local Price and Product Mix		Currency		Volume		Portfolio and Other
Agriculture	$	7.2	(11	)	2		(7	)	(5	)	(1	)	$	3.8	(4	)	2		(5	)	(1	)	—
Electronics & Communications	1.1		(12	)	(4	)	(2	)	(6	)	—		0.5		(13	)	(3	)	(1	)	(9	)	—
Industrial Biosciences	0.6		(7	)	(4	)	(6	)	3		—		0.4		1		2		(3	)	1		1
Nutrition & Health	1.6		(8	)	—		(8	)	1		(1	)	0.8		(1	)	—		(4	)	3		—
Performance Chemicals	2.9		(13	)	(5	)	(4	)	(2	)	(2	)
Performance Materials	2.8		(11	)	(3	)	(6	)	5		(7	)	1.2		(10	)	(5	)	(2	)	(3	)	—
Safety & Protection	1.8		(7	)	—		(5	)	3		(5	)
Protection Solutions													0.7		(8	)	(1	)	(2	)	(5	)	—

Agriculture - ~~Second~~First quarter ~~2015~~2016 segment net sales of ~~$3,218~~$3,786 million decreased ~~$397~~$151 million, or 114 percent, driven by lower volumes and the negative impact of currency of $194 million, partially offset by higher local prices and improved mix of Pioneer's new corn hybrids and soybean varieties. Decreased volumes are due to reduced soybean seed sales, lower crop protection volumes, and reductions in global corn planted area. PTOI of $774 million decreased $15 million, or 2 percent, on lower sales and a $84 million negative currency impact, partially offset by improved productivity and disciplined cost actions and the absence of $47 million associated with the 2014 restructuring program in second quarter 2014. Second quarter 2015 PTOI included charges of $4 million associated with the 2014 restructuring program.

~~Table of Contents~~

Year-to-date segment sales of $7,155 million decreased $854 million, or 11 percent on the negative impact of currency of $528 million and lower volumes, partially offset by improved mix of Pioneer's new corn hybrids and soybean varieties and pricing actions in Europe to mitigate the impact of a stronger U.S. dollar. Decreased volumes are due to reduced soybean sales, reductions in global corn planted area and the timing of seed shipments. PTOI of $1,948 million decreased $283 million or 13 percent on $290 million negative currency impact and lower sales partially offset by disciplined cost actions, increases in pricing from new product mix, insurance recoveries of $35 million for recovery of costs for customer claims related to the use of the Imprelis® herbicide and the absence of $47 million associated with the 2014 restructuring program in second quarter 2014. See Notes 10 to the interim Consolidated Financial Statements for more information related to the Imprelis^® ~~matter.~~

~~Outlook~~ ~~For the full year 2015, sales are expected to be in the high-single-digits percent lower with PTOI in the low-twenty percent range below 2014~~primarily due to the negative impact of currency and lower volumes, partially offset with higher local price from pricing actions to mitigate currency impacts in Europe and Brazil and improved mix from new products in North America corn seed. Lower insecticide and soybean seed volumes were partially offset by ~~pricing~~increased corn seed volumes in North America due to higher expected acreage, higher corn seed volume in Brazil from the Safrinha season and increased demand for sunflower seed in Europe. Operating earnings of $1,101 million decreased $37 million, or 3 percent, primarily due to an $83 million negative currency impact, lower volumes and about a $40 million negative impact from the shutdown of the La Porte manufacturing facility due to lost sales, fixed overhead costs and inventory write-offs, partially offset by local price and product mix gains ~~productivity~~ and ~~disciplined~~ cost ~~management.~~savings.

Outlook Full year 2016 segment net sales are expected to be down low-single digits percent as local price and product mix gains are more than offset by the negative impact of currency. Higher corn seed volumes are expected to be offset by lower insecticide and soybean seed volumes. Full year operating earnings are expected to be up mid-single digits percent as cost savings and local price and product mix gains more than offset the negative impact of currency.

Electronics & Communications - ~~Second~~First quarter ~~2015~~2016 segment net sales of ~~$534~~$452 million decreased ~~$83~~$65 million, or 13 percent, primarily due to competitive pressures impacting ~~sales of~~ Solamet^®paste, lower demand for products for the consumer electronics market, lower pricing from the pass-through of lower metals prices and the negative impact of currency, partially offset by volume growth infor Tedlar^®film ~~in photovoltaics~~for photovoltaics. Operating earnings of $59 million decreased $20 million, or 25 percent, as lower sales and ~~products for the consumer electronics market. PTOI of $104~~a $16 million ~~increased $83 million due to productivity gains and the absence of $68 million associated with the 2014 restructuring program in second quarter 2014,~~litigation expense were partially offset by ~~lower sales. Second quarter 2015 PTOI included $11 million benefit associated with the 2014 restructuring program.~~cost savings.

~~Year-to-date~~Outlook Full year 2016 segment net sales are expected to be down low-single digits percent with second half growth in photovoltaics and consumer electronics which will mostly offset first half declines. Full year operating earnings are expected to be up low-teens percent due to second half sales improvement and cost savings.

Industrial Biosciences - First quarter 2016 segment net sales of ~~$1,055~~$352 million increased $2 million, or 1 percent, primarily due to higher pricing and volume from new product introductions in bioactives and increased demand for biomaterials, mostly offset by the negative impact of currency and lower demand for clean technologies offerings. Operating earnings of $63 million increased $9 million, or 17 percent, reflecting the absence of cost from the write-off of a prior year acquisition related indemnification asset in clean technologies and improved mix from new products, partially offset by a negative impact from currency.

Outlook Full year 2016 segment net sales are expected to be about flat. Volume improvement, pricing, the impact of new product introductions in bioactives, including increased market penetration in animal nutrition and home and personal care, and the portfolio impact from the fourth quarter 2015 acquisition of enzyme and technology assets from Dyadic International Inc. are expected to be offset by lower demand for clean technology offerings and the negative impact of currency. Full year 2016 operating earnings are expected to be up by the low-teens percent, primarily due mix enrichment and cost savings.

Nutrition & Health - First quarter 2016 segment net sales of $801 million decreased ~~$142~~$12 million, or 121 percent, ~~on lower volumes and reduced selling prices~~primarily due to ~~competitive pressures impacting sales of Solamet~~^® ~~paste, lower pricing from the pass-through of metals prices, and~~ the negative impact of currency, partially offset by ~~increased volumes in Tedlar~~^® ~~film~~broad-based volume growth led by probiotics, cultures, ingredient systems, texturants and ~~products for the consumer electronics market. PTOI~~specialty proteins. Operating earnings of ~~$189~~$104 million increased ~~$93~~$18 million, or 9721 percent, ~~driven by productivity gains~~as volume growth and ~~the absence of $68 million associated~~cost savings more than offset a negative currency impact.

Outlook Full year 2016 segment net sales are expected to be about flat with ~~the 2014 restructuring program~~continued strength in ~~second quarter 2014, partially~~probiotics and cultures, offset by the ~~above mentioned competitive pressures~~negative impact of currency. Full year 2016 operating earnings are expected to be up in the low-twenty percent range, as mix enrichment and cost savings more than offset the negative impact of currency.

Performance Materials - First quarter 2016 segment net sales of $1,249 million decreased $132 million, or 10 percent, primarily due lower local price, lower volume and a negative impact from currency. Lower price was driven by lower ethylene prices and competitive pressure in commodity product lines. Lower volumes in ethylene and ethylene-based products were partially offset by increased demand in Asia Pacific automotive markets, primarily in China. Operating earnings of $273 million decreased $44 million, or 14 percent, primarily due to lower sales and a $19 million negative impact from currency, partially offset by lower costs.

Outlook ~~For the full~~Full year ~~2015,~~2016 segment net sales are expected to be ~~down high-single-digits percent on lower sales of Solamet~~^® ~~paste, lower metal prices~~about flat and ~~currency. PTOI is expected to increase in the low-single-digits percent as productivity gains will more than offset the negative impacts of currency.~~

~~Industrial Biosciences -~~ Second quarter 2015 segment sales of $288 million decreased $29 million, or 9 percent driven by the negative impact of currency of $24 million, lower pricing, and lower biomaterials sales in U.S. residential home improvement markets, partially offset by volume growth in enzymes, principally for animal nutrition, health and personal care and food markets. PTOI of $49 million decreased $8 million, or 14 percent, on lower pricing and the negative impact of currency, partially offset by productivity improvements and increased enzyme demand. Second quarter 2015 and second quarter 2014 PTOI included charges of $1 million and $2 million, respectively, associated with the 2014 restructuring program.

Year-to-date segment sales of $573 million decreased $45 million, or 7 percent due to the negative impact of currency of $39 million and lower prices and lower demand for biomaterials, partially offset by enzyme volume growth discussed above. PTOI of $105 million decreased $8 million, or 7 percent driven by lower pricing and the negative impact of currency, partially offset with productivity gains and enzyme demand.

~~Outlook~~ ~~For the~~ full year 2015, sales are expected to be down mid-single-digits percent due primarily to currency. PTOI is expected to be down low-single-digits percent as higher volumes, prices and improved mix will be more than offset by currency.

~~Nutrition & Health -~~ Second quarter 2015 segment sales of $826 million decreased $100 million, or 11 percent, driven by the negative impact of currency of $83 million and the pass-through of lower soybean crush commodity prices. Volume growth in probiotics, texturants, cultures and ingredient systems was offset by lower volumes in specialty proteins. PTOI of $99 million increased $2 million, or 2 percent driven by productivity gains, mostly offset by the negative impact of currency of $12 million. Second quarter 2015 and second quarter 2014 PTOI included charges of $4 million and $8 million, respectively, associated with the 2014 restructuring program.

Year-to-date segment sales of $1,639 million decreased $148 million, or 8 percent, driven by the negative impact of currency of $151 million partially offset with volume growth. Volume growth in probiotics, texturants, cultures and ingredient systems was partially offset by lower volumes in specialty proteins. PTOI of $188 million decreased $2 million, or 1 percent driven by the negative impact of currency of $23 million, partially offset by volume and productivity gains.

~~Table of Contents~~

~~Outlook~~ For the full year 2015, sales are expected to be mid-single-digits percent lower as volume gains are more than offset by currency. PTOI is expected to be about flat as both product margin expansion and productivity gains are offset by currency.

~~Performance Chemicals -~~ Second quarter 2015 segment sales of $1,502 million decreased $194 million, or 11 percent, and PTOI of $54 million decreased $178 million or 77 percent, driven by lower prices primarily for titanium dioxide, and the negative impact of currency of $68 million for segment sales and $43 million for PTOI. Titanium dioxide prices continue to be negatively impacted by strong regional competition. PTOI decline was partially offset by the absence of a $19 million charge associated with the 2014 restructuring program in second quarter 2014. The second quarter 2015 PTOI included a $61 million charge associated with the Chemours restructuring program and a $2 million benefit associated with the 2014 restructuring program.

Year-to-date 2015 segment sales of $2,866 million decreased $421 million, or 13 percent, and PTOI of $183 million decreased $255 million or 58 percent, driven by lower prices and volumes primarily for titanium dioxide, and the negative impact of currency of $124 million for segment sales and $71 million for PTOI.

~~Performance Materials -~~ Second quarter 2015 segment sales of $1,365 million decreased $217 million, or 14 percent, driven by the negative impact of currency of $104 million, the portfolio changes from the sale of Glass Laminating Solutions/Vinyls (GLS/Vinyls) and lower ethylene pricing. Partially offsetting the declines are increased volumes of ethylene as prior year ethylene sales were constrained due to a scheduled outage at the Orange, Texas ethylene unit. Second quarter PTOI of $309 million decreased $356 million or 54 percent, driven by the absence of the $391 million pre-tax gain on the sale of GLS/Vinyls in the second quarter 2014 and the negative impact of currency of $42 million, partially offset by lower product costs, productivity and ethylene volume growth. Second quarter 2015 and 2014 PTOI included a charge of $2 million and $29 million, respectively, associated with the 2014 restructuring plan.

Year-to-date 2015 segment sales of $2,776 million decreased $340 million, or 11 percent, driven by the portfolio changes from the sale of GLS/Vinyls, the negative impact of currency of $180 million and lower ethylene pricing. Partially offsetting the declines are increased volumes of ethylene as prior year ethylene sales were constrained in advance of a scheduled outage at the Orange, Texas ethylene unit. PTOI of $636 million decreased $322 million or 34 percent, driven by the absence of the $391 million pre-tax gain on the sale of GLS/Vinyls in the second quarter 2014 and the negative impact of currency of $66 million, partially offset by volume growth of ethylene and lower product costs.

~~Outlook~~ For the full year 2015, sales are expected to be down about 10 percent due primarily to currency, portfolio changes from the sale of GLS/Vinyls, and lower ethylene prices. PTOI is expected to be down mid-single-digits percent as volume growth is more than offset by the negative impacts from currency and portfolio changes.

~~Safety & Protection -~~ ~~Second quarter 2015 segment sales of $925 million decreased $104 million or 10 percent due to the portfolio impact of the Sontara~~^® ~~divestiture and the negative impact of currency of $47 million. Increased demand for Tyvek~~^® ~~protective material, including medical packaging and protective garments, was offset by lower demand, particularly in the oil and gas industry, impacting Nomex~~^® thermal resistant fiber and Sustainable Solutions offerings. PTOI of $308 million increased $130 million or 73 percent, driven by a pre-tax gain of $112 million, net of legal expenses, recorded in other income, net related to the company’s settlement of a legal claim. In addition, PTOI includes the negative impact of currency of $20 million and higher costs associated with the first quarter outage at the Chambers Works facility in New Jersey that were offset by productivity improvements and the absence of a $31 million charge associated with the 2014 restructuring program in second quarter 2014. The second quarter 2015 PTOI included a $1 million benefit associated with the 2014 restructuring program.

~~Year-to-date 2015 segment sales of $1,834 million decreased $142 million or 7 percent due to the portfolio impact of the Sontara~~^®~~divestiture and the negative impact of currency of $85 million partially offset by volume growth driven by increased demand for Tyvek~~^®protective material. PTOI of $492 million increased $139 million or 39 percent, driven by a pre-tax gain of $112 million, net of legal expenses, recorded in other income, net related to the company’s settlement of a legal claim. In addition, PTOI includes the negative impact of currency of $35 million and higher costs associated with the first quarter outage at the Chambers Works facility in New Jersey offset by productivity improvements and the absence of a $31 million charge associated with the 2014 restructuring program in second quarter 2014.

~~Outlook~~ ~~For the full year 2015, sales~~2016 operating earnings are expected to be down in the ~~low-single-digits~~mid-single digits percent range, as volume growth ~~in Tyvek~~is anticipated to be more than offset by lower local price and the negative impact of currency. Full year 2015 operating earnings included $49 million of benefits from a joint venture, the sale of a business and realization of tax benefits associated with a manufacturing site.

Protection Solutions - ^®,First quarter 2016 segment net sales of $729 million decreased $61 million, or 8 percent, primarily due to lower volume, the negative impact of currency, and lower local price. Volume declines in Nomex^®~~, and~~ thermal-resistant fiber, Kevlar^® high-strength ~~materials will be more than offset by the negative impacts of currency~~material and ~~portfolio changes from the Sontara~~Tyvek^® ~~divestiture. PTOI is~~protective material were driven by weakness in the oil and gas industry, delays in military spending, and lower industrial market demand. Operating earnings of $176 million increased $9 million, or 5 percent, on lower costs and improved plant utilization at the Chambers Works facility, partially offset by lower sales and a $6 million negative currency impact.

Outlook Full year 2016 segment net sales are expected to ~~increase low-single-digits~~be about flat as volume growth is anticipated to offset price and the negative impact of currency. Full year 2016 operating earnings are expected to be up by the high single digits percent, ~~range~~primarily due to ~~volume growth and productivity.~~lower costs.

~~Table of Contents~~

Liquidity & Capital Resources

Information related to the company's liquidity and capital resources can be found in the company's ~~2014~~2015 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Liquidity and Capital Resources. Discussion below provides the updates to this information for the ~~six~~three months ended ~~June 30, 2015.~~March 31, 2016.

(Dollars in millions) June 30, 2015 December 31, 2014
Cash, cash equivalents and marketable securities $ 5,302
$ 7,034
Total debt 12,735
10,656

Total debt as of June 30, 2015 was $12.7 billion, a $2.0 billion increase from $10.7 billion as of December 31, 2014. The increase in total debt is primarily due to the debt issued by Chemours. These Chemours arrangements were offset by a $488 million debt exchange, in which the company retired $152 million of 1.95% notes, $277 million of 2.75% notes, and $59 million of 5.25% notes all due in 2016. The company paid a premium of $20 million in connection with the early retirement of the $488 million of 2016 notes. The company's debt was also reduced due to the pay down of maturing debt.

In connection with the separation, the company received dividend proceeds from Chemours in May 2015 of $3,923 million comprised of a cash distribution of $3,416 million and a distribution in-kind of $507 million in the form of ten-year notes maturing in 2025 with a fixed interest rate of 7%. Chemours financed the dividend payment through issuance of approximately $4,000 million of debt comprised of $1,500 million aggregate principal amount of borrowing under a senior secured term loan facility with variable interest rates and a term of seven years, $1,350 million of 6.625% senior unsecured notes due 2023, $750 million of 7% senior unsecured notes due 2025 and €360 million of 6.125% senior unsecured notes due 2023. Since at June 30, 2015, Chemours was a wholly-owned, consolidated subsidiary of the company, DuPont’s Condensed Consolidated Balance Sheet for the period ended June 30, 2015 includes Chemours’ Debt. The transfer of the liability associated with Chemours’ Debt, as well as all other assets and liabilities transferred to Chemours, will be reflected in DuPont’s financial statements in the third quarter of 2015.



(Dollars in millions)	March 31, 2016		December 31, 2015
Cash, cash equivalents and marketable securities	$	4,789	$	6,206
Total debt	9,751		8,807

The company's cash, cash equivalents and marketable securities at ~~June 30, 2015~~March 31, 2016 and December 31, ~~2014~~2015 are ~~$5.3~~$4.8 billion and ~~$7.0~~$6.2 billion, respectively. The ~~$1.7~~$1.4 billion decrease was primarily due to ~~cash used to fund normal~~seasonal working capital ~~needs, payments~~requirements.

Total debt as of March 31, 2016 was $9.8 billion, a $1.0 billion increase from $8.8 billion as of December 31, 2015, due primarily to borrowings under the ~~shareholder dividends,~~Term Loan Facility and the Repurchase Facility, discussed below, as well as increased commercial paper borrowings, net of debt ~~retirement,~~maturities.

In March 2016, the company entered into a credit agreement that provides for a three-year, senior unsecured term loan facility in the aggregate principal amount of $4.5 billion (the Term Loan Facility). DuPont may make up to seven term loan borrowings within one year of the closing date and amounts repaid or prepaid are not available for subsequent borrowings. The proceeds from the borrowings under the Term Loan Facility will be used for the company's general corporate purposes including debt repayment, working capital and share repurchases. The Term Loan Facility matures in March 2019 at which time all outstanding borrowings, including accrued but unpaid interest, become immediately due and payable. As of March 31, 2016, the company had borrowed $500 million and had unused commitments of $4.0 billion under the Term Loan Facility.

In addition, in March 2016, the company amended the existing revolving credit facility to reduce the aggregate principal amount of commitments from $4 billion to $3 billion consistent with lower expected commercial paper borrowings.

The Term Loan Facility and the amended revolving credit facility contain customary representations and warranties, affirmative and negative covenants, and events of default that are typical for companies with similar credit ratings and generally consistent with those applicable to DuPont’s long-term public debt. The Term Loan Facility and the amended revolving credit facility contain a financial covenant requiring that the ratio of Total Indebtedness to Total Capitalization for DuPont and its consolidated subsidiaries not exceed 0.6667. At March 31, 2016, the company was in compliance with this financial covenant.

The Term Loan Facility and the amended revolving credit facility impose additional affirmative and negative covenants on DuPont and its subsidiaries after the closing of the proposed merger with Dow, subject to certain limitations, including to:

not sell, lease or otherwise convey to DowDuPont, its shareholders or its non-DuPont subsidiaries, any assets or properties of DuPont or its subsidiaries unless the aggregate amount of revenues attributable to all such assets and properties so conveyed after the merger does not exceed 30% of the consolidated revenues of DuPont and its subsidiaries as of December 31, 2015; and

not guarantee any indebtedness or other obligations of DowDuPont, Dow or their respective subsidiaries (other than of DuPont and its subsidiaries).

The Term Loan Facility and the amended revolving credit facility will terminate, and the loans and other amounts thereunder will become due and payable, upon the sale, transfer, lease or other disposition of all or substantially all of the assets of the Agriculture line of business to DowDuPont, its shareholders or any of its non-DuPont subsidiaries.

In February 2016, in line with seasonal agricultural working capital requirements, the company entered into a committed receivable repurchase agreement of up to $1 billion (the Repurchase Facility) that expires on November 30, 2016. Under the Repurchase Facility, the company may sell a portfolio of available and eligible outstanding customer notes receivables within the Agriculture segment to participating institutions and simultaneously agree to repurchase at a future date. See further discussion of this facility in Note 10 to the interim Consolidated Financial Statements.

The company has access to approximately $8.6 billion in unused credit lines, an increase of $3.7 billion from $4.9 billion as of December 31, 2015 due to the Term Loan Facility and Repurchase Facility discussed above, partially offset by ~~cash received from issuance~~the amended revolving credit facility discussed above. These unused credit lines provide support to meet short-term liquidity needs and general corporate purposes including letters of ~~Chemours debt.~~credit.

Summary of Cash Flows

Cash used for operating activities was ~~$2.0~~$1.8 billion for the ~~six~~three months ended ~~June 30, 2015, essentially equal~~March 31, 2016 compared to $2.1 billion during the same period in 2015. The $0.3 billion decrease in cash used for operations was due primarily to lower working capital requirements and the positive currency impact that offsets cash used by foreign currency exchange contract settlements that is included in investing activities. The positive currency impacts were partially offset by the prepayment to Chemours.

Cash provided by investing activities was $27 million for the three months ended March 31, 2016 compared to $140 million of cash used during the same period last year. The ~~decline~~change was primarily the result of proceeds received from the sale of an entity, the sale of marketable securities and reduced purchases of property, plant and equipment. The reduction in ~~net income coupled with higher income tax payments was offset by various working capital benefits.~~

~~Cash used for investing activities was $1.0 billion for the six months ended~~ ~~June 30, 2015~~ ~~compared to $0.2 billion for the same period last year. The $0.8 billion increase in cash used for investing activities~~purchases of property, plant and equipment was primarily due to the absence of ~~proceeds from the sale of the GLS/Vinyls business which occurred~~Chemours in ~~2014 coupled with an increase in investment in short-term financial instruments~~2016. This was partially offset by ~~an increase~~the decrease in cash ~~settlements~~received from foreign currency contracts. Purchases of property, plant and equipment increased by $0.2 billion primarily due to an adjustment to reflect these purchases on a cash basis. The impact of the adjustment was not material to prior periods.contract settlements.

Cash provided by financing activities was ~~$1.0~~$0.7 billion for the ~~six~~three months ended ~~June 30, 2015~~March 31, 2016 compared to ~~$2.4~~$0.9 billion of cash used ~~for financing activities for~~during the same period last year. The ~~$3.4 billion increase in cash provided by financing activities~~change was primarily due ~~primarily~~ to ~~Chemours~~increased borrowings ~~coupled with~~and lower ~~repurchase of~~ common ~~stock.~~stock repurchases.

Dividends paid to shareholders during the ~~six~~three months ended ~~June 30, 2015~~March 31, 2016 totaled ~~$0.9~~$0.3 billion. In ~~July 2015,~~January 2016, the Board of Directors declared a ~~third~~first quarter ~~common stock~~ dividend of $0.38 per share. ~~The~~In April 2016, the Board of Directors declared a second quarter dividend of $0.38 per share. With the first and second quarter 2016 dividends, the company has paid quarterly consecutive dividends since the company’s first dividend in the fourth quarter 1904.

In January 2014, the company's Board of Directors authorized a $5 billion share buyback plan that replaced the 2011 plan. During the three ~~and six~~ months ended ~~June, 30,~~March 31, 2015, the company purchased and retired ~~1.0~~3.6 million ~~and 4.6 million~~ shares ~~respectively,~~ in the open market for a total cost of $282 million, which offset the dilution from employee compensation plans in the first ~~and second~~ quarter of 2015. ~~As of June 30, 2015,~~There were no share repurchases under this plan in the ~~company has purchased 34.7 million shares at a total cost of $2.4 billion under the plan.~~first quarter 2016. There is no required completion date for the remaining stock purchases.

~~Table of Contents~~

In the first quarter 2015, DuPont announced its intention to buy back shares of about $4 billion using the distribution proceeds received from Chemours. In connection with the completion of the spin-off of Chemours, the Board of Directors authorized the use of the distribution proceeds to buy back shares of the company's common stock as follows: $2 billion to be purchased and retired by December 31, 2015, which was completed during 2015, with the remainder to be purchased and retired by December 31, 2016. ~~The company expects to use an accelerated~~There were no share ~~repurchase~~repurchases under this plan in ~~connection with~~ the first quarter 2016. DuPont's objective continues to be to complete the remaining $2 billion stock buyback by year ~~end.~~end 2016. As a result of the planned merger with Dow, the company will not repurchase shares until after the shareholder vote on the merger. After the vote the company will evaluate the opportunities to enter the market and plans to make repurchases.

See ~~Part II, Item 2 and~~ Note 1112 to the interim Consolidated Financial Statements for additional information.

Guarantees and Off-Balance Sheet Arrangements

For detailed information related to Guarantees, Indemnifications, and Obligations for Equity Affiliates and Others, see the company's ~~2014~~2015 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Off- Balance Sheet Arrangements, and Note 1011 to the interim Consolidated Financial Statements.

~~Table of Contents~~

Contractual Obligations

Information related to the company's contractual obligations at December 31, ~~2014~~2015 can be found in the company's ~~2014~~2015 Annual Report, Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations, Off-Balance Sheet Arrangements. The company's long-term debt obligations at June 30, 2015 increased by $3.7 billion versus prior year end primarily due to $3.9 billion associated with the debt issued by Chemours. See Note 9 to the interim Consolidated Financial Statements and Liquidity & Capital Resources for additional information.


Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

See Note ~~12,~~13, “Financial Instruments”, to the interim Consolidated Financial Statements. See also Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk, of the company's ~~2014~~2015 Annual Report for information on the company's utilization of financial instruments and an analysis of the sensitivity of these instruments.

~~Table of Contents~~

Item 4. CONTROLS AND PROCEDURES

a) Evaluation of Disclosure Controls and Procedures

The company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

As of ~~June 30, 2015~~March 31, 2016, the company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective.

b) Changes in Internal Control over Financial Reporting

There has been no change in the company's internal control over financial reporting that occurred during the quarter ended ~~June 30, 2015~~March 31, 2016 that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting.

~~Table of Contents~~

PART II. OTHER INFORMATION


Item 1.	LEGAL PROCEEDINGS

The company is subject to various litigation matters, including, but not limited to, product liability, patent infringement, antitrust claims, and claims for third party property damage or personal injury stemming from alleged environmental torts. Information regarding certain of these matters is set forth below and in Note 1011 to the interim Consolidated Financial Statements.

~~Imprelis~~^® ~~Herbicide Claims Process~~

~~Information related to this matter is included in Note 10 to the interim Consolidated Financial Statements under the heading Imprelis~~^®.

PFOA: Environmental and Litigation Proceedings

For purposes of this report, the term PFOA means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms. Information related to this matter is included in Note 1011 to the interim Consolidated Financial Statements under the heading PFOA.

~~LaPorte~~La Porte Plant, ~~LaPorte,~~La Porte, Texas

The U.S. Environmental Protection Agency (EPA) conducted a multimedia inspection at the ~~LaPorte~~La Porte facility in January 2008. DuPont, EPA and the Department of Justice (DOJ) began discussions in the ~~Fall~~fall 2011 relating to the management of certain materials in the facility's waste water treatment system, hazardous waste management, flare and air emissions. These negotiations continue.

~~LaPorte~~La Porte Plant, ~~LaPorte,~~La Porte, Texas - Crop Protection

On November 15, 2014 there was a release of methyl mercaptan at the company’s ~~LaPorte~~La Porte facility. The release occurred at the site’s Crop Protection unit resulting in four employee fatalities inside the unit. DuPont ~~is continuing its investigation into the incident. Several~~continues to cooperate with those governmental agencies ~~also are~~still conducting ~~their own~~ investigations. ~~DuPont is cooperating with these agency reviews.~~ In May 2015, the Occupational Safety & Health Administration (OSHA) cited the company for eight serious and one repeat violation with an associated penalty of $99,000. The company is contesting OSHA’s findings.

~~LaPorte~~La Porte Plant, ~~LaPorte,~~La Porte, Texas - OSHA Process Safety Management (PSM) Audit

In 2015, OSHA conducted a PSM audit of the Crop Protection and Fluoroproducts units at the ~~LaPorte~~La Porte Plant. In July 2015, OSHA cited the company for three willful, one repeat and four serious PSM violations and placed the company in its Severe Violator Enforcement Program. OSHA has proposed a penalty of $273,000. The company is contesting OSHA’s findings.

Sabine Plant, Orange, Texas

In June 2012, DuPont began discussions with DOJ and EPA related to a multimedia ~~inspection~~inspections that EPA conducted at the Sabine facility in March ~~2009.~~2009 and December 2015. The discussions involve the management of materials in the facility's waste water treatment system, hazardous waste management, flare and air ~~emissions.~~emissions, including leak detection and repair.

~~Yerkes Plant, Buffalo, New York~~

In March 2015, DuPont began discussions with the EPA related to alleged violations at the Yerkes facility of a Risk Management Plan (RMP) and General Duty Clause under the Clean Air Act (CAA). The allegations stem from a 2010 incident at the facility during which a welding contractor ignited residual vapors in an empty storage vessel.

Item 1A. RISK FACTORS

There have been no material changes in the company's risk factors discussed in Part I, Item 1A, Risk Factors, in the company's ~~2014~~2015 Annual Report.

~~Table of Contents~~

~~Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~

~~Issuer Purchases of Equity~~

~~In January 2014, the company's Board of Directors authorized a $5 billion share buyback plan. There is no required completion date for purchases under this plan.~~

~~In April and May 2015, the company purchased and retired 0.3 million and 0.7 million shares, respectively,~~Item 5. OTHER INFORMATION

As noted in ~~the open market under the $5 billion share buyback plan.~~

~~See Part I, Item 2 on page 37 of this report and~~ Note 111 to the interim Consolidated Financial Statements, ~~for additional information.~~effective January 1, 2016, the company adopted Accounting Standards Update (ASU) No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes. The amendments under the new guidance require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position on a retrospective basis. In conjunction with the early adoption of ASU No. 2015-17 in the first quarter 2016, the company also retrospectively reclassified deferred charges previously recorded in the current deferred income taxes line item to prepaid expenses on the Consolidated Balance Sheets.

The following ~~table summarizes information with respect to~~line items within the ~~company's purchase~~Consolidated Balance Sheets as of ~~its common stock during~~December 31, 2015 and 2014, respectively, were affected by the ~~three months ended June 30, 2015:~~ASU adoption:

Month Total Number of Shares Purchased
Average Price
Paid per Share
Total Number of
Shares Purchased as Part of Publicly Announced Program
Approximate Value
of Shares that May
Yet Be Purchased
Under the Program⁽¹⁾(Dollars in millions)
April:
Open Market Purchases 293,840
$73.60 293,840

May:
Open Market Purchases 700,000
$70.32 700,000

Total 993,840
993,840
$ 2,647


¹	~~Represents approximate value of shares that may yet be purchased under the 2014 plan.~~

~~Item 4. MINE SAFETY DISCLOSURES~~



	2015							2014
(Dollars in millions)	As reported		As reported under ASU No. 2015-17		Change: (Decrease) / Increase			As reported		As reported under ASU No. 2015-17		Change: (Decrease) / Increase
Assets
Current assets
Prepaid expenses	$	248	$	398	$	150		$	264	$	452	$	188
Deferred income taxes	518		—		(518		)	532		—		(532		)

Deferred income taxes	$	3,431	$	3,799	$	368		$	3,734	$	4,078	$	344

Liabilities and Equity
Current liabilities
Income taxes	$	210	$	173	$	(37	)	$	534	$	487	$	(47	)

Deferred income taxes	$	380	$	417	$	37		$	459	$	506	$	47

~~Information regarding mine safety and other regulatory actions at~~

DuPont Sustainable Solutions, previously within the company's ~~surface mine~~Safety & Protection segment (now Protection Solutions) was comprised of two business units: clean technologies and consulting solutions. Effective January 1, 2016, the clean technologies business is reported in ~~Starke, Florida~~the Industrial Biosciences segment and the consulting solutions business unit is ~~included in Exhibit 95 to~~reported within Other. The following reflects the revised segment information for the reportable segments impacted by this ~~report.~~2016 segment reorganization for the years ended December 31, 2015, 2014 and 2013:



(Dollars in millions)	2015			2014			2013
Industrial Biosciences
Net Sales	$	1,478		$	1,624		$	1,631
Operating Earnings	243			269			232
Significant pre-tax charges not included in segment operating earnings	(61		)	(20		)	(1		)
Depreciation and amortization	101			102			98
Equity in earnings of affiliates	7			8			2
Segment net assets	3,154			3,241			3,325
Affiliate net assets	41			45			48
Purchases of property, plant and equipment	84			94			84
Protection Solutions
Net Sales	$	3,039		$	3,304		$	3,229
Operating Earnings	641			672			553
Significant pre-tax benefits (charges) not included in segment operating earnings	105			(45		)	6
Depreciation and amortization	156			168			178
Equity in earnings of affiliates	23			28			21
Segment net assets	2,295			2,339			2,464
Affiliate net assets	71			78			83
Purchases of property, plant and equipment	96			98			101
Other
Net Sales	$	184		$	213		$	237
Operating Earnings	(235		)	(233		)	(208		)
Significant pre-tax (charges) benefits not included in segment operating earnings	(40		)	(10		)	1
Depreciation and amortization	6			8			9
Equity in earnings of affiliates	(30		)	(47		)	(48		)
Segment net assets	258			316			122
Affiliate net assets	23			16			19
Purchases of property, plant and equipment	132			203			115


Item 6.	EXHIBITS

Exhibits: The list of exhibits in the Exhibit Index to this report is incorporated herein by reference.

~~Table of Contents~~

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	E. I. DU PONT DE NEMOURS AND COMPANY
	(Registrant)

	Date:	~~July 28, 2015~~April 26, 2016


	By:	/s/ Nicholas C. Fanandakis

		Nicholas C. Fanandakis
		Executive Vice President and
		Chief Financial Officer
		(As Duly Authorized Officer and
		Principal Financial and Accounting Officer)

~~Table of Contents~~

EXHIBIT INDEX



Exhibit Number		Description

3.1		Company’s Restated Certificate of Incorporation (incorporated by reference to Exhibit 99.2 to the company’s Current Report on Form 8-K (Commission file number 1-815) dated June 1, 2015).

3.2		Company’s Bylaws, as last amended effective ~~August 12, 2013~~October 22, 2015 (incorporated by reference to Exhibit 3.2 to the ~~company’s~~company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended September 30, ~~2013)~~2015).

4		The company agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of the company and its subsidiaries.

10.1*		The DuPont Stock Accumulation and Deferred Compensation Plan for Directors, as last amended effective January 1, 2009 (incorporated by reference to Exhibit 10.1 to the company's Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2013).

10.2*		Company’s Supplemental Retirement Income Plan, as last amended effective ~~June 4,~~December 18, 1996 (incorporated by reference to Exhibit 10.2 to the company’s Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2011).

10.3*		Company’s Pension Restoration Plan, as last amended effective June 29, ~~2015.~~2015 (incorporated by reference to Exhibit 10.3 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2015).

10.4*		Company’s Rules for Lump Sum Payments, as last amended effective May 15, ~~2014.~~2014 (incorporated by reference to Exhibit 10.4 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2015).

10.5*		Company’s Stock Performance Plan, as last amended effective January 25, 2007 (incorporated by reference to Exhibit 10.5 to the company’s Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2011).

10.6*		Company’s Equity and Incentive Plan, as amended October 23, 2014 (incorporated by reference to Exhibit ~~10.6~~10.06 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended September 30, 2014).

10.7*		Form of Award Terms under the company’s Equity and Incentive Plan (incorporated by reference to Exhibit 10.7 to the company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2013).

10.8*		Company’s Retirement Savings Restoration Plan, as last amended effective May 15, 2014. (incorporated by reference to Exhibit ~~10.8~~10.08 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2014).

10.9*		Company’s Retirement Income Plan for Directors, as last amended January 2011 (incorporated by reference to Exhibit 10.9 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 31, 2012).

10.10*		Company's Senior Executive Severance Plan, ~~adopted on August 12, 2013~~as amended and restated effective December 10, 2015 (incorporated by reference to Exhibit ~~10.11~~10.10 to the company's ~~Quarterly~~Annual Report on Form ~~10-Q~~10-K (Commission file number 1-815) for the ~~period~~year ended ~~September 30, 2013)~~December 31, 2015). The company agrees to furnish supplementally a copy of any omitted schedules to the Commission upon request.

~~Table of Contents~~



Exhibit Number		Description

10.11*		Supplemental Deferral Terms for Deferred Long Term Incentive Awards and Deferred Variable Compensation Awards (incorporated by reference to Exhibit 10.12 to the company's Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2013).

10.12*		Form of 2014 Award Terms under the Company's Equity and Incentive Plan (incorporated by reference to Exhibit 10.13 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 31, 2014).

10.13*		Company’s Management Deferred Compensation Plan, as last amended effective April 15, 2014 (incorporated by reference to Exhibit 10.13 to the company's Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2014).

10.14*		~~Consulting~~Separation Agreement dated October ~~22, 2014,~~5, 2015, by and between ~~E.I.~~E. I. du Pont de Nemours and Company and ~~Thomas M. Connelly~~Ellen J. Kullman (incorporated by reference to Exhibit ~~10.4~~10.1 to the company's ~~Quarterly~~Current Report on ~~10-Q~~Form 8-K (Commission file ~~number~~ 1-815) ~~for the period ended September 30, 2014)~~dated October 5, 2015).

10.15*		Form of 2015 Award Terms under the Company's Equity and Incentive Plan (incorporated by reference to Exhibit ~~10.14~~10.15 to the company's Quarterly Report on 10-Q (Commission file number 1-815) for the period ended March 31, 2015).

10.16*		Letter Agreement dated January 4, 2016 and, entered January 18, 2016, by and between the Company and Mr. James C. Borel (incorporated by reference to Exhibit 10.1 to the company's Current Report on Form 8-K (Commission file number 1-815) dated January 22, 2016).

10.17**		Separation Agreement by and between the Company and The Chemours Company (incorporated by reference to reference to Exhibit 2.1 to the company’s Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015).

~~10.17~~10.18		Tax Matters Agreement by and between the Company and The Chemours Company (incorporated by reference to reference to Exhibit 2.2 to the company’s Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015).

10.19**		Agreement and Plan of Merger by and between the Company and The Dow Chemical Company, dated as of December 11, 2015 (incorporated by reference to Exhibit 2.1 to the company's Current Report on Form 8-K (Commission file number 1-815) dated December 11, 2015).

10.20**		Master Repurchase Agreement with Cooperative Rabobank, U.A. (New York Branch) and The Bank of Tokyo Mitsubishi UFJ Ltd. (New York Branch) dated as of February 3, 2016 (incorporated by reference to Exhibit 10.20 to the company's Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2015).

10.21**		Master Framework Agreement with Cooperative Rabobank, U.A. (New York Branch) and The Bank of Tokyo Mitsubishi UFJ Ltd. (New York Branch) dated as of February 3, 2016 (incorporated by reference to Exhibit 10.21 to the company's Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2015).

10.22**		Form of 2016 Award Terms under the Company's Equity and Incentive Plan.

12		Computation of Ratio of Earnings to Fixed Charges.

~~18.1~~		Preferability Letter of Independent Registered Public Accounting Firm (incorporated by reference to Exhibit 18.1 to the company's Quarterly Report on Form 10-Q for the period ended September 30, 2014).

31.1		Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Executive Officer.

31.2		Rule 13a-14(a)/15d-14(a) Certification of the company’s Principal Financial Officer.



32.1		Section 1350 Certification of the company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.

32.2		Section 1350 Certification of the company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.

95		~~Mine Safety Disclosures.~~

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

~~Table of Contents~~




101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

*Management contract or compensatory plan or arrangement.

**DuPont hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to such agreement to the U.S. Securities and Exchange Commission upon request.



Delaware		51-0014090
(State or other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)



Large Accelerated Filer x		Accelerated Filer o

Non-Accelerated Filer o		Smaller reporting company o



			Page
Part I	Financial Information

Item 1.	Consolidated Financial Statements (Unaudited)
	Consolidated Income Statements		3
	Consolidated Statements of Comprehensive Income		4
	Condensed Consolidated Balance Sheets		5
	Condensed Consolidated Statements of Cash Flows		6
	Notes to the Consolidated Financial Statements
	Note 1.	Summary of Significant Accounting Policies	7
	Note 2.	~~Divestitures and Other Transactions~~Proposed Merger with Dow Chemical	8
	Note 3.	~~Employee Separation / Asset Related Charges, Net~~Divestitures and Other Transactions	9
	Note 4.	~~Other Income,~~Employee Separation / Asset Related Charges, Net	1011
	Note 5.	Other Income, ~~Taxes~~Net	1012
	Note 6.	Income Taxes	13
	Note 7.	Earnings Per Share of Common Stock	11
	~~Note 7.~~	~~Inventories~~	1113
	Note 8.	~~Other Intangible Assets~~Inventories	1213
	Note 9.	~~Long-Term Borrowings~~Other Intangible Assets	1314
	Note 10.	~~Commitments~~Short-Term and ~~Contingent Liabilities~~Long-Term Borrowings	1315
	Note 11.	~~Stockholders’ Equity~~Commitments and Contingent Liabilities	1715
	Note 12.	~~Financial Instruments~~Stockholders’ Equity	1918
	Note 13.	~~Long-Term Employee Benefits~~Financial Instruments	2420
	Note 14.	~~Segment Information~~Long-Term Employee Benefits	25
	Note 15.	~~Subsequent Events~~Segment Information	26

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		28
	Cautionary Statements About Forward-Looking Statements		28
	Recent Developments		2830
	Results of Operations		3031
	Recent Accounting Pronouncements		33
	Segment Reviews		34
	Liquidity & Capital Resources		3736
	Contractual Obligations		3938

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		3938
Item 4.	Controls and Procedures		4039

Part II	Other Information

Item 1.	Legal Proceedings		4140
Item 1A.	Risk Factors		4140
Item 2.5.	~~Unregistered Sales of Equity Securities and Use of Proceeds: Issuer Purchases of Equity~~Other Information		42
~~Item 4.~~	~~Mine Safety Disclosures~~		4241
Item 6.	Exhibits		42
Signature			43
Exhibit Index			44


	Three Months Ended				Six Months Ended				Three Months Ended
	June 30,				June 30,				March 31,
	2015		2014		2015		2014		2016			2015
Net sales	$	8,595	$	9,706	$	17,767	$	19,834	$	7,405		$	7,837
Other income, net	283		408		481		425
Total	8,878		10,114		18,248		20,259
Cost of goods sold	5,280		5,999		10,833		11,999		4,242			4,516
Other operating charges	349		300		632		586		185			148
Selling, general and administrative expenses	1,371		1,473		2,683		2,909		1,128			1,220
Research and development expense	515		545		1,014		1,063		418			479
Other income, net									(372		)	(199		)
Interest expense	127		94		211		197		92			84
Employee separation / asset related charges, net	61		263		99		263		77			38
Total	7,703		8,674		15,472		17,017
Income before income taxes	1,175		1,440		2,776		3,242
Provision for income taxes	230		366		796		723
Income from continuing operations before income taxes									1,635			1,551
Provision for income taxes on continuing operations									406			530
Income from continuing operations after income taxes									1,229			1,021
Income from discontinued operations after income taxes									3			14
Net income	945		1,074		1,980		2,519		1,232			1,035
Less: Net income attributable to noncontrolling interests	5		4		9		10		6			4
Net income attributable to DuPont	$	940	$	1,070	$	1,971	$	2,509	$	1,226		$	1,031
Basic earnings per share of common stock:
Basic earnings per share of common stock from continuing operations									$	1.40		$	1.12
Basic earnings per share of common stock from discontinued operations									—			0.01
Basic earnings per share of common stock	$	1.04	$	1.16	$	2.17	$	2.72	$	1.40		$	1.13
Diluted earnings per share of common stock:
Diluted earnings per share of common stock from continuing operations									$	1.39		$	1.11
Diluted earnings per shares of common stock from discontinued operations									—			0.01
Diluted earnings per share of common stock	$	1.03	$	1.15	$	2.15	$	2.70	$	1.39		$	1.13
Dividends per share of common stock	$	0.49	$	0.45	$	0.96	$	0.90	$	0.38		$	0.47


	June 30, 2015			December 31, 2014			March 31, 2016			December 31, 2015
Assets
Current assets
Cash and cash equivalents	$	4,746		$	6,910		$	4,166		$	5,300
Marketable securities	556			124			623			906
Accounts and notes receivable, net	8,308			6,005			6,917			4,643
Inventories	6,514			7,841			5,482			6,140
Prepaid expenses	296			279			677			398
Deferred income taxes	625			589
Total current assets	21,045			21,748			17,865			17,387
Property, plant and equipment, net of accumulated depreciation (June 30, 2015 - $20,256; December 31, 2014 - $19,942)	13,061			13,386
Property, plant and equipment, net of accumulated depreciation (March 31, 2016 - $14,621; December 31, 2015 - $14,346)							9,649			9,784
Goodwill	4,455			4,529			4,256			4,248
Other intangible assets	4,286			4,580			4,071			4,144
Investment in affiliates	895			886			689			688
Deferred income taxes	3,223			3,349			4,142			3,799
Other assets	1,141			1,058			1,129			1,116
Total	$	48,106		$	49,536		$	41,801		$	41,166
Liabilities and Equity
Current liabilities
Accounts payable	$	3,399		$	4,822		$	2,773		$	3,398
Short-term borrowings and capital lease obligations	647			1,423			1,625			1,165
Income taxes	613			547			171			173
Other accrued liabilities	4,046			5,848			4,386			5,580
Total current liabilities	8,705			12,640			8,955			10,316
Long-term borrowings and capital lease obligations	12,088			9,233			8,126			7,642
Other liabilities	13,188			13,819			13,700			12,591
Deferred income taxes	472			466			422			417
Total liabilities	34,453			36,158			31,203			30,966
Commitments and contingent liabilities
Stockholders’ equity
Preferred stock	237			237			237			237
Common stock, $0.30 par value; 1,800,000,000 shares authorized; Issued at June 30, 2015 - 991,875,000; December 31, 2014 - 992,020,000	298			298
Common stock, $0.30 par value; 1,800,000,000 shares authorized; Issued at March 31, 2016 - 960,450,000; December 31, 2015 - 958,388,000							288			288
Additional paid-in capital	11,389			11,174			11,140			11,081
Reinvested earnings	17,838			17,045			15,400			14,510
Accumulated other comprehensive loss	(9,446		)	(8,707		)	(9,951		)	(9,396		)
Common stock held in treasury, at cost (87,041,000 shares at June 30, 2015 and December 31, 2014)	(6,727		)	(6,727		)
Common stock held in treasury, at cost (87,041,000 shares at March 31, 2016 and December 31, 2015)							(6,727		)	(6,727		)
Total DuPont stockholders’ equity	13,589			13,320			10,387			9,993
Noncontrolling interests	64			58			211			207
Total equity	13,653			13,378			10,598			10,200
Total	$	48,106		$	49,536		$	41,801		$	41,166



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934



	Three Months Ended
	March 31
	2016		2015
Depreciation	$	—	$	62
Amortization of intangible assets	—		1
Purchases of property, plant and equipment	—		150



	Employee Separation Costs
Charges to income for the three and six months ended June 30, 2015	$	61
Payments	(8		)
Balance as of June 30, 2015	$	53



	Severance and Related Benefit Costs			Asset Related Charges			Other Non-Personnel Charges¹			Total
Balance at December 31, 2015	$	648		$	—		$	32		$	680
Payments	(124		)	—			(20		)	(144		)
Net translation adjustment	3			—			—			3
Other adjustments	(44		)	37			9			2
Asset write-offs	—			(37		)	—			(37		)
Balance as of March 31, 2016	$	483		$	—		$	21		$	504


^1.	Other non-personnel charges consist of contractual obligation costs.



	Employee Separation Costs			Other Non-Personnel Charges ¹			Total
Balance at December 31, 2014	$	264		$	4		$	268
Payments	(77		)	(1		)	(78		)
Net translation adjustment	(7		)	—			(7		)
Other adjustments	—			—			—
Balance as of June 30, 2015	$	180		$	3		$	183


^11.	Other non-personnel charges consist of contractual obligation costs.


^23.	Miscellaneous income and expenses, net, includes interest items, certain insurance recoveries and gains related to litigation settlements and other items.


	June 30, 2015							December 31, 2014							March 31, 2016							December 31, 2015
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Intangible assets subject to amortization (Definite-lived):
Customer lists	$	1,637	$	(500	)	$	1,137	$	1,706	$	(470	)	$	1,236	$	1,635	$	(552	)	$	1,083	$	1,621	$	(529	)	$	1,092
Patents	476		(215		)	261		493		(199		)	294		457		(232		)	225		454		(220		)	234
Purchased and licensed technology	1,777		(1,223		)	554		1,789		(1,074		)	715		1,204		(736		)	468		1,173		(649		)	524
Trademarks	31		(15		)	16		31		(14		)	17		26		(14		)	12		26		(13		)	13
Other ¹	189		(72		)	117		207		(88		)	119		180		(76		)	104		180		(72		)	108
	4,110		(2,025		)	2,085		4,226		(1,845		)	2,381		3,502		(1,610		)	1,892		3,454		(1,483		)	1,971

Intangible assets not subject to amortization (Indefinite-lived):
In-process research and development	77		—			77		29		—			29		71		—			71		72		—			72
Microbial cell factories	306		—			306		306		—			306		306		—			306		306		—			306
Pioneer germplasm	1,062		—			1,062		1,064		—			1,064		1,048		—			1,048		1,048		—			1,048
Trademarks/tradenames	756		—			756		800		—			800		754		—			754		747		—			747
	2,201		—			2,201		2,199		—			2,199		2,179		—			2,179		2,173		—			2,173
Total	$	6,311	$	(2,025	)	$	4,286	$	6,425	$	(1,845	)	$	4,580	$	5,681	$	(1,610	)	$	4,071	$	5,627	$	(1,483	)	$	4,144


^1.	Excludes equity affiliates.


	June 30, 2015			December 31, 2014			March 31, 2016			December 31, 2015
Finished products	$	4,006		$	4,628		$	3,401		$	3,779
Semi-finished products	1,853			2,451			1,559			1,780
Raw materials, stores and supplies	1,128			1,255			721			783
	6,987			8,334			5,681			6,342
Adjustment of inventories to a last-in, first-out (LIFO) basis	(473		)	(493		)	(199		)	(202		)
Total	$	6,514		$	7,841		$	5,482		$	6,140


^1 1.	Primarily consists of sales and grower networks, marketing and manufacturing alliances and noncompetition agreements.


^22.	Existing guarantees for equity affiliates' liquidity needs in normal operations.


	Short-Term		Long-Term		Total		Short-Term		Long-Term		Total
Obligations for customers and suppliers¹:
Bank borrowings (terms up to 7 years)	$	155	$	73	$	228
Leases on equipment and facilities (terms up to 3 years)	—		1		1
Bank borrowings (terms up to 6 years)							$	96	$	16	$	112
Obligations for equity affiliates²:
Bank borrowings (terms up to 1 year)	180		—		180		178		—		178
Obligations for Chemours³:
Chemours' purchase obligations (final expiration - 2018)							22		11		33
Total	$	335	$	74	$	409	$	296	$	27	$	323


^11.	Existing guarantees for customers and suppliers, as part of contractual agreements.



	Three Months Ended									Three Months Ended									Affected Line Item in Consolidated Income Statements
	June 30, 2015									June 30, 2014
	Pre-Tax			Tax			After-Tax			Pre-Tax			Tax			After-Tax
Cumulative translation adjustment⁽³⁾	$	197		$	—		$	197		$	(59	)	$	—		$	(59	)
Net revaluation and clearance of cash flow hedges to earnings:
Additions and revaluations of derivatives designated as cash flow hedges	8			(3		)	5			(12		)	4			(8		)	See (1) below
Clearance of hedge results to earnings:
Foreign currency contracts	(2		)	1			(1		)	1			(1		)	—			Net sales
Commodity contracts	7			(3		)	4			12			(4		)	8			Cost of goods sold
Net revaluation and clearance of cash flow hedges to earnings	13			(5		)	8			1			(1		)	—
Pension benefit plans:
Net (loss) gain	(2		)	1			(1		)	(103		)	33			(70		)	See (1) below
Effect of foreign exchange rates	(62		)	18			(44		)	—			—			—			See (1) below
Reclassifications to net income:
Amortization of prior service (benefit) cost	(1		)	—			(1		)	—			—			—			See (2) below
Amortization of loss	210			(75		)	135			150			(52		)	98			See (2) below
Curtailment loss	—			—			—			4			(1		)	3			See (2) below
Settlement loss	4			(1		)	3			2			—			2			See (2) below
Pension benefit plans, net	149			(57		)	92			53			(20		)	33
Other benefit plans:
Reclassifications to net income:
Amortization of prior service benefit	(52		)	18			(34		)	(53		)	19			(34		)	See (2) below
Amortization of loss	19			(6		)	13			14			(5		)	9			See (2) below
Other benefit plans, net	(33		)	12			(21		)	(39		)	14			(25		)
Other comprehensive income (loss)	$	326		$	(50	)	$	276		$	(44	)	$	(7	)	$	(51	)


^2.	These amounts represent changes in accumulated other comprehensive loss excluding changes due to reclassifying amounts to the interim Consolidated Income Statements. See Notes 13 and 14 for additional information.


^23.	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost of the company's pension and other long-term employee benefit plans. See Note 1314 for additional information.



	Cumulative Translation Adjustment			Net Revaluation and Clearance of Cash Flow Hedges to Earnings			Pension Benefit Plans			Other Benefit Plans			Unrealized Gain on Securities		Total
2015
Balance January 1, 2015	$	(1,016	)	$	(6	)	$	(7,949	)	$	262		$	2	$	(8,707	)
Other comprehensive (loss) income before reclassifications	(992		)	(11		)	25			—			—		(978		)
Amounts reclassified from accumulated other comprehensive loss	—			7			274			(42		)	—		239
Balance June 30, 2015	$	(2,008	)	$	(10	)	$	(7,650	)	$	220		$	2	$	(9,446	)


^1.	Available-for-sale securities are reported at estimated fair value with unrealized gains and losses reported as component of accumulated other comprehensive loss. Proceeds from the sale of available-for-sale securities were $260 in the three months ended March 31, 2016.


^2.	Held-to-maturity investments are reported at amortized cost.


		Fair Value Using Level 2 Inputs					Fair Value Using Level 2 Inputs
	Balance Sheet Location	June 30, 2015		December 31, 2014		Balance Sheet Location	March 31, 2016		December 31, 2015
Asset derivatives:
Derivatives designated as hedging instruments:
Interest rate swaps¹	Accounts and notes receivable, net	$	—	$	1
Derivatives not designated as hedging instruments:
Foreign currency contracts	Accounts and notes receivable, net	—		10		Accounts and notes receivable, net	$	51	$	74
		—		11
Derivatives not designated as hedging instruments:
Foreign currency contracts²	Accounts and notes receivable, net	61		254

Total asset derivatives³		$	61	$	265
Cash collateral^1,2	Other accrued liabilities	$	4	$	47
Total asset derivatives¹							$	51	$	74
Cash collateral						Other accrued liabilities	$	—	$	7

Liability derivatives:
Derivatives designated as hedging instruments:
Foreign currency contracts	Other accrued liabilities	$	1	$	10

Derivatives not designated as hedging instruments:
Foreign currency contracts	Other accrued liabilities	54		62		Other accrued liabilities	$	138	$	80
Commodity contracts	Other accrued liabilities	1		1		Other accrued liabilities	1		4
		55		63
Total liability derivatives³		$	56	$	73
Total liability derivatives¹							$	139	$	84


¹	~~Cash collateral held as of~~ ~~June 30, 2015~~ ~~and~~ ~~December 31, 2014~~ ~~represents~~ $0 ~~and~~ $6~~, respectively, related to interest rate swap derivatives designated as hedging instruments.~~


^31.	The company's derivative assets and liabilities subject to enforceable master netting arrangements totaled $3644 at ~~June 30, 2015~~March 31, 2016 and $6735 at December 31, ~~2014~~2015.



	Amount of Gain (Loss) Recognized in OCI¹ (Effective Portion)					Amount of Gain (Loss) Recognized in Income²
Three Months Ended June 30,	2015		2014			2015			2014			Income Statement Classification
Derivatives designated as hedging instruments:
Fair value hedges:
Interest rate swaps	$	—	$	—		$	—		$	(6	)	Interest expense
Cash flow hedges:
Foreign currency contracts	1		—			2			(1		)	Net sales
Commodity contracts	7		(12		)	(7		)	(12		)	Cost of goods sold
	8		(12		)	(5		)	(19		)
Derivatives not designated as hedging instruments:
Foreign currency contracts	—		—			(7		)	(70		)	Other income, net³
Foreign currency contracts	—		—			(3		)	—			Net sales
Commodity contracts	—		—			3			(1		)	Cost of goods sold
	—		—			(7		)	(71		)
Total derivatives	$	8	$	(12	)	$	(12	)	$	(90	)


^2 2.	For cash flow hedges, this represents the effective portion of the gain (loss) reclassified from accumulated OCI into income during the period. For the three ~~and three and six~~ months ended ~~June 30, 2015~~March 31, 2016 and ~~2014~~2015, there was no material ineffectiveness with regard to the company's cash flow hedges.



Three Months Ended June 30,	Agriculture¹			Electronics & Communications			Industrial Biosciences			Nutrition & Health			Performance Chemicals			Performance Materials			Safety & Protection			Other				Total
2015
Segment sales	$	3,218		$	534		$	288		$	826		$	1,502		$	1,365		$	925		$	2			$	8,660
Less: Transfers	—			6			3			—			28			27			1			—				65
Net sales	3,218			528			285			826			1,474			1,338			924			2				8,595
PTOI	774		²	104		²	49		²	99		²	54		^2,3	309		²	308		^2,7	(60		)	²	1,637

2014
Segment sales	$	3,615		$	617		$	317		$	926		$	1,696		$	1,582		$	1,029		$	1			$	9,783
Less: Transfers	5			4			4			—			48			15			1			—				77
Net sales	3,610			613			313			926			1,648			1,567			1,028			1				9,706
PTOI	789		⁴	21		⁴	57		⁴	97		⁴	232		⁴	665		^4,5	178		⁴	(84		)	⁴	1,955



Six Months Ended June 30,	Agriculture¹			Electronics & Communications			Industrial Biosciences			Nutrition & Health			Performance Chemicals			Performance Materials			Safety & Protection			Other				Total
2015
Segment sales	$	7,155		$	1,055		$	573		$	1,639		$	2,866		$	2,776		$	1,834		$	3			$	17,901
Less: Transfers	—			10			8			—			57			57			2			—				134
Net sales	7,155			1,045			565			1,639			2,809			2,719			1,832			3				17,767
PTOI	1,948		^2,6	189		²	105		²	188		²	183		^2,3	636		²	492		^2,7	(163		)	^2,8	3,578

2014
Segment sales	$	8,009		$	1,197		$	618		$	1,787		$	3,287		$	3,116		$	1,976		$	2			$	19,992
Less: Transfers	8			7			7			—			105			29			2			—				158
Net sales	8,001			1,190			611			1,787			3,182			3,087			1,974			2				19,834
PTOI	2,231		⁴	96		⁴	113		⁴	190		⁴	438		⁴	958		^4,5	353		⁴	(176		)	⁴	4,203



Three Months Ended March 31,	Agriculture¹		Electronics & Communications		Industrial Biosciences		Nutrition & Health		Performance Materials		Protection Solutions		Other			Total
2016
Net sales	$	3,786	$	452	$	352	$	801	$	1,249	$	729	$	36		$	7,405
Operating earnings	1,101		59		63		104		273		176		(59		)	1,717

2015
Net sales	$	3,937	$	517	$	350	$	813	$	1,381	$	790	$	49		$	7,837
Operating earnings	1,138		79		54		86		317		167		(31		)	1,810


^11.	As of ~~June 30, 2015~~March 31, 2016, Agriculture net assets were $~~10,246~~7,454, an increase of $~~3,551~~703 from ~~$6,695~~$6,751 at December 31, ~~2014~~2015. The increase was primarily due to higher trade receivables related to normal seasonality in the sales and cash collections cycle.



	Three Months Ended March 31,
	2016			2015
Total segment operating earnings	$	1,717		$	1,810
Significant pre-tax charges not included in segment operating earnings	(68		)	(2		)
Non-operating pension and other postretirement employee benefit costs	(74		)	(86		)
Net exchange (losses) gains¹	(121		)	79
Corporate income (expenses)^2,3,4,5	273			(166		)
Interest expense	(92		)	(84		)
Income from continuing operations before income taxes	$	1,635		$	1,551


^2.	Includes transaction costs associated with the planned merger with Dow and related activities of $(24), in the three months ended March 31, 2016, which were recorded in selling, general and administrative expenses in the company's interim Consolidated Income Statements. See Note 2 for additional information.


⁵	~~Included a gain of $391 recorded in other income, net associated with the sale of GLS/Vinyls. See Note 2 for additional information.~~